ZA200101894B - Method for preparing novel fenofibrate galenic formulations, galenic formualtions obtained and applications. - Google Patents

Method for preparing novel fenofibrate galenic formulations, galenic formualtions obtained and applications. Download PDF

Info

Publication number: ZA200101894B
Authority: ZA; South Africa
Prior art keywords: fenofibrate; granulation; liquid medium; water; granular material
Prior art date: 1998-09-17

Application number

ZA200101894A

Other languages

English (en)

Inventor

Claude Lareulle

Rene Gimet

Dominique Toselli

Original Assignee

Cll Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

2001-03-07

Publication date

2003-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9530543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200101894(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-07 Application filed by Cll Pharma filed Critical Cll Pharma

2003-01-07 Publication of ZA200101894B publication Critical patent/ZA200101894B/en

Links

YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 title claims abstract description 107
229960002297 fenofibrate Drugs 0.000 title claims abstract description 86
239000000203 mixture Substances 0.000 title claims abstract description 48
238000000034 method Methods 0.000 title claims abstract description 37
238000009472 formulation Methods 0.000 title claims abstract description 28
239000003814 drug Substances 0.000 claims abstract description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
239000008187 granular material Substances 0.000 claims abstract description 24
239000007788 liquid Substances 0.000 claims abstract description 16
239000004094 surface-active agent Substances 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
238000001035 drying Methods 0.000 claims abstract description 10
239000007903 gelatin capsule Substances 0.000 claims description 33
238000005469 granulation Methods 0.000 claims description 22
230000003179 granulation Effects 0.000 claims description 22
239000002245 particle Substances 0.000 claims description 20
230000001225 therapeutic effect Effects 0.000 claims description 12
239000000843 powder Substances 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 6
238000004513 sizing Methods 0.000 claims description 6
239000011230 binding agent Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
238000004040 coloring Methods 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
239000000796 flavoring agent Substances 0.000 claims description 5
235000019634 flavors Nutrition 0.000 claims description 5
239000000314 lubricant Substances 0.000 claims description 5
239000003607 modifier Substances 0.000 claims description 5
108010010803 Gelatin Proteins 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
239000001369 metatartaric acid Substances 0.000 claims 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract description 2
208000006575 hypertriglyceridemia Diseases 0.000 abstract description 2
238000011282 treatment Methods 0.000 description 19
MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 13
229960000701 fenofibric acid Drugs 0.000 description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
229920002472 Starch Polymers 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
230000036470 plasma concentration Effects 0.000 description 9
235000019698 starch Nutrition 0.000 description 9
239000008107 starch Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
230000008901 benefit Effects 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
239000007787 solid Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000011734 sodium Substances 0.000 description 5
235000015424 sodium Nutrition 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000031891 intestinal absorption Effects 0.000 description 4
229960001021 lactose monohydrate Drugs 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
-1 chalk Polymers 0.000 description 3
239000008119 colloidal silica Substances 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
230000007704 transition Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000015924 Lithiasis Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010039020 Rhabdomyolysis Diseases 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229940053392 fenofibrate 150 mg Drugs 0.000 description 1
229940020832 fenofibrate 200 mg Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Polymers 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000003387 muscular Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

ZA200101894A 1998-09-17 2001-03-07 Method for preparing novel fenofibrate galenic formulations, galenic formualtions obtained and applications. ZA200101894B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9811611A FR2783421B1 (fr)	1998-09-17	1998-09-17	Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications

Publications (1)

Publication Number	Publication Date
ZA200101894B true ZA200101894B (en)	2003-01-07

Family

ID=9530543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200101894A ZA200101894B (en)	1998-09-17	2001-03-07	Method for preparing novel fenofibrate galenic formulations, galenic formualtions obtained and applications.

Country Status (16)

Country	Link
EP (1)	EP1112064B1 (cs)
JP (1)	JP2002526438A (cs)
KR (1)	KR100712032B1 (cs)
AT (1)	ATE230979T1 (cs)
AU (1)	AU5523599A (cs)
BR (1)	BR9913782A (cs)
CA (1)	CA2342742A1 (cs)
CZ (1)	CZ298634B6 (cs)
DE (1)	DE69904954D1 (cs)
ES (1)	ES2190819T3 (cs)
FR (1)	FR2783421B1 (cs)
MX (1)	MXPA01002801A (cs)
PL (1)	PL194847B1 (cs)
SK (1)	SK284950B6 (cs)
WO (1)	WO2000016749A1 (cs)
ZA (1)	ZA200101894B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982281B1 (en)	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) *	1999-07-09	2004-05-28	Ethypharm Lab Prod Ethiques	Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7276249B2 (en)	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (fr)	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
RS20100015A (sr)	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
GB0119480D0 (en)	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en)	2001-09-21	2006-11-22	Schering Corporation	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
AU2003263480A1 (en) *	2002-09-24	2004-04-19	Ranbaxy Laboratories Limited	Oral pharmaceutical compositions of fenofibrate having high bioavailability
JP2006508188A (ja)	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de)	2003-03-07	2008-10-09	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EP1923053A1 (en) *	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2842547A1 (en)	2013-08-27	2015-03-04	Freund Pharmatec Ltd.	Improved fenofibrate compositions
EP2878311A1 (en)	2013-11-27	2015-06-03	Freund Pharmatec Ltd.	Solubility Enhancement for Hydrophobic Drugs
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN104352466A (zh) *	2014-11-17	2015-02-18	辰欣药业股份有限公司	一种非诺贝特组合物及其制剂
US20180147215A1 (en)	2016-11-28	2018-05-31	Lipocine Inc.	Oral testosterone undecanoate therapy
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2627696B1 (fr) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
FR2722984B1 (fr) *	1994-07-26	1996-10-18	Effik Lab	Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
SI9500173B (sl) *	1995-05-19	2002-02-28	Lek,	Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
DE19608750A1 (de) *	1996-03-06	1997-09-11	Durachemie Gmbh & Co Kg	Verfahren zur Herstellung von Fenofibrat-Präparaten
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

1998
- 1998-09-17 FR FR9811611A patent/FR2783421B1/fr not_active Expired - Fee Related
1999
- 1999-09-10 BR BR9913782-8A patent/BR9913782A/pt not_active IP Right Cessation
- 1999-09-10 KR KR1020017003463A patent/KR100712032B1/ko not_active Expired - Fee Related
- 1999-09-10 PL PL346714A patent/PL194847B1/pl not_active IP Right Cessation
- 1999-09-10 JP JP2000573710A patent/JP2002526438A/ja active Pending
- 1999-09-10 AU AU55235/99A patent/AU5523599A/en not_active Abandoned
- 1999-09-10 CA CA002342742A patent/CA2342742A1/fr not_active Abandoned
- 1999-09-10 ES ES99941732T patent/ES2190819T3/es not_active Expired - Lifetime
- 1999-09-10 CZ CZ20010979A patent/CZ298634B6/cs not_active IP Right Cessation
- 1999-09-10 AT AT99941732T patent/ATE230979T1/de not_active IP Right Cessation
- 1999-09-10 SK SK355-2001A patent/SK284950B6/sk not_active IP Right Cessation
- 1999-09-10 EP EP99941732A patent/EP1112064B1/fr not_active Revoked
- 1999-09-10 WO PCT/FR1999/002155 patent/WO2000016749A1/fr not_active Ceased
- 1999-09-10 DE DE69904954T patent/DE69904954D1/de not_active Expired - Lifetime
- 1999-09-10 MX MXPA01002801A patent/MXPA01002801A/es unknown
2001
- 2001-03-07 ZA ZA200101894A patent/ZA200101894B/en unknown

Also Published As

Publication number	Publication date
KR100712032B1 (ko)	2007-04-27
DE69904954D1 (de)	2003-02-20
MXPA01002801A (es)	2002-04-08
SK284950B6 (sk)	2006-03-02
CZ2001979A3 (cs)	2001-08-15
JP2002526438A (ja)	2002-08-20
EP1112064A1 (fr)	2001-07-04
SK3552001A3 (en)	2001-09-11
WO2000016749A1 (fr)	2000-03-30
KR20010075182A (ko)	2001-08-09
CZ298634B6 (cs)	2007-11-28
PL346714A1 (en)	2002-02-25
FR2783421A1 (fr)	2000-03-24
AU5523599A (en)	2000-04-10
FR2783421B1 (fr)	2000-11-24
ES2190819T3 (es)	2003-08-16
BR9913782A (pt)	2001-06-05
PL194847B1 (pl)	2007-07-31
EP1112064B1 (fr)	2003-01-15
ATE230979T1 (de)	2003-02-15
CA2342742A1 (fr)	2000-03-30

Publication	Publication Date	Title
KR100712032B1 (ko)	2007-04-27	신규한 페노피브레이트 갈레노스 제제의 제조방법, 제조된갈레노스 제제 및 용도
US4556678A (en)	1985-12-03	Sustained release propranolol tablet
CA2406373C (en)	2010-06-29	Controlled release paracetamol composition
NL8302842A (nl)	1985-01-02	Naproxeen en naproxeen natrium tabletten met een geregelde afgifte.
US5399360A (en)	1995-03-21	Pharmaceutical compositions
JPH0714876B2 (ja)	1995-02-22	フェノフィブレートを含有する治療用組成物およびその製造方法
AU2001260212A1 (en)	2002-01-24	Composition
JP2012025778A (ja)	2012-02-09	フェノフィブラート含有組成物
CA2435714C (en)	2011-02-22	Fenofibrate tablets
EP1663174A1 (en)	2006-06-07	Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
EP1414433B1 (en)	2006-04-12	Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
WO2003013501A1 (en)	2003-02-20	Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
HK1050138A1 (en)	2003-06-13	Novel galenical form for oral administration with prolonged release of molsidomine
US20070160663A1 (en)	2007-07-12	Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
KR950007229B1 (ko)	1995-07-07	케토티펜을 함유한 약학적 조성물
HK1053601B (en)	2010-03-26	Pharmaceutical composition for the controlled release of paracetamol